GlobeNewswire·Nov 13, 2026, 7:00 AM ET

Jade Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Jade Biosciences expects to initiate the JADE101 Phase 3 EVERGREEN trial in IgA nephropathy during Q4 2026.
The JADE101 Phase 2 JUNIPER trial remains ongoing with interim data expected in Q2 2027.
The JADE201 Phase 1 trial in rheumatoid arthritis is ongoing with interim data anticipated in 2027.
The JADE301 Phase 1 trial in dermatomyositis is expected to start in Q4 2026 with interim data in H2 2027.
Cash, cash equivalents, and investments totaled $475.7 million as of September 30, 2026, providing a runway into Q4 2028.
Brad Dahms was expanded to Chief Financial Officer and Chief Business Officer to lead finance, investor relations, business development, and corporate strategy.
R\&D expenses reached $30.8 million for Q3 2026, up $8.8 million from the prior year period.
G\&A expenses were $8.8 million for Q3 2026, an increase of $3.4 million compared to Q3 2025.
The company reported a net loss of $35.1 million for Q3 2026, compared to $25.2 million in the same period last year.
Preclinical data for JADE301 showed selective high-affinity binding to IFN-β, greater potency than a comparator, \& a 25-day half-life in non-human primates.